Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCamellia Regulatory News (CAM)

Share Price Information for Camellia (CAM)

Share Price is delayed by 15 minutes
Get Live Data
5,650.00    0.00 (0.00%)
Bid:
5,550.00
Ask:
5,650.00
Spread: 100.00 (1.802%)
Market Cap: £142.82m
CAM Live PriceLast checked at - London Stock Exchange

Intraday Camellia Share Chart

BF&M Strategic Review

30 Jun 2022 07:00

RNS Number : 7264Q
Camellia PLC
30 June 2022
 

30 June 2022

Camellia Plc

 

(the "Company" or the "Group")

 

Associate company update

 

Camellia Plc (CAM.L) announces that its 37.4% owned associate company, BF&M Limited ("BF&M"), a listed Bermudian insurance business, yesterday issued a statement that in order to maximise shareholder value, it has initiated a review of strategic alternatives for the business. This may include a range of outcomes for BF&M, including, inter alia, the sale of BF&M. The full text of BF&M's announcement can be found in Appendix 1 to this announcement.

 

There can be no guarantee as to the outcome of the BF&M strategic review. A further announcement will be made in due course as and when appropriate.

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

 

Enquiries

 

Camellia Plc 01622 746655

Malcolm Perkins, Chairman

Susan Walker, Chief Financial Officer

 

Panmure Gordon 020 7886 2500

Nominated Adviser and Broker

Emma Earl

Erik Anderson

 

Maitland/AMO

PR

William Clutterbuck 07785 292617

 

 

 

 

 

 

 

Appendix 1 BF&M announces Strategic Review

Hamilton, Bermuda. 29 June 2022- BF&M Limited (BF&M or the 'Company') (BSX:BFM) announced today that, following discussions with its principal 37.4% shareholder, the Board of Directors ( the 'Board') has initiated a review of strategic alternatives (the Strategic Review) to maximise shareholder value and which may include the sale of the Company.

 

The Board has established a special committee (Special Committee), chaired by Group Chairman and Chief Executive Officer John Wight and including Jennifer Reynolds and Anthony Joaquin, both independent directors, to oversee the Strategic Review. The Special Committee has retained Desjardins Capital Markets to assist it in this process.

 

John Wight stated: 'Throughout and beyond the Strategic Review process, BF&M will remain focused on enhancing corporate value by steadily carrying out business activities, delivering excellent customer service and executing on our long-term strategy.'

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSESESUEESEDM
Date   Source Headline
6th Feb 20257:00 amRNSTransaction in Own Shares
5th Feb 20257:00 amRNSTransaction in Own Shares
4th Feb 20258:29 amRNSTransaction in Own Shares
3rd Feb 20257:00 amRNSTransaction in Own Shares
31st Jan 20257:00 amRNSTransaction in Own Shares
30th Jan 20257:00 amRNSTrading Update
27th Jan 20257:00 amRNSTransaction in Own Shares
22nd Jan 20257:00 amRNSTransaction in Own Shares
13th Jan 20257:00 amRNSTransaction in Own Shares
9th Jan 20257:00 amRNSTransaction in Own Shares
8th Jan 20257:00 amRNSTransaction in Own Shares
3rd Jan 20257:00 amRNSTransaction in Own Shares
24th Dec 20247:00 amRNSTransaction in Own Shares
20th Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
17th Dec 20247:00 amRNSTransaction in Own Shares
9th Dec 20247:00 amRNSDirector/PDMR Shareholding
9th Dec 20247:00 amRNSTransaction in Own Shares
6th Dec 20247:00 amRNSDisposal
5th Dec 20247:00 amRNSDisposal
11th Nov 20248:06 amRNSSale of Bangladesh associate companies
31st Oct 202411:37 amRNSDisposal
25th Oct 202412:51 pmRNSHolding(s) in Company
17th Oct 20247:00 amRNSTrading Statement
6th Sep 202411:44 amRNSInterim Report 2024
6th Sep 20247:00 amRNSHalf-year Report
1st Jul 20247:00 amRNSDirector Changes
28th Jun 20241:00 pmRNSUpdate on BF&M Transaction
7th Jun 202411:14 amRNSResult of AGM
6th Jun 20247:00 amRNSTrading Update
1st May 202412:30 pmRNSAnnual Report & Notice of Annual General Meeting
29th Apr 20247:00 amRNSFinal Results
25th Apr 20247:00 amRNSDirector Changes
28th Mar 202412:11 pmRNSUpdate on BF&M disposal
4th Jan 20244:00 pmRNSRefocussing investments & Bardsley England update
27th Sep 202310:03 amRNSTrading Update
1st Sep 20235:21 pmRNSInterim Report 2023
1st Sep 20237:00 amRNSHalf-year Report
17th Jul 20237:00 amRNSDirector Changes
9th Jun 202312:08 pmRNSResult of AGM
8th Jun 20237:00 amRNSAGM Trading Statement
6th Jun 202312:00 pmRNSSale of holding in BF&M Limited
11th May 202311:04 amRNSAnnual Report and Notice of AGM
4th May 20237:00 amRNSFinal Results
20th Mar 20237:00 amRNSChange of Registered Office Address
8th Mar 20237:00 amRNSTrading Update
30th Jan 20237:00 amRNSBF&M Strategic Review Conclusion
10th Jan 20239:01 amRNSCompletion of Disposal of ACS&T
19th Dec 20227:00 amRNSDisposal of ACS&T and Relocation of Head Office
7th Dec 20227:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.